Publication:
Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin

Simple item page
dc.contributor.authorNieto, Yago
dc.contributor.authorMartín, Miguel
dc.contributor.authorAlonso-Romero, José Luis
dc.contributor.authorCasado, Antonio
dc.contributor.authorAyala, Francisco
dc.contributor.authorLópez-Martín, José Antonio
dc.contributor.authorRodríguez-Lescure, Alvaro
dc.contributor.authorDíaz-Rubio, Eduardo
dc.contributor.departmentMedicina
dc.date.accessioned2024-11-08T08:15:32Z
dc.date.available2024-11-08T08:15:32Z
dc.date.issued1998
dc.description© 1998 kluwer Academic Publisher. This document is the Published version of a Published Work that appeared in final form in Breast Cancer Research and Treatment. To access the final edited and published work see https://doi.org/10.1023/a:1006062018355
dc.description.abstractDoxorubicin-resistant metastatic breast cancer (MBC) is a very poor prognosis scenario, where only taxanes have shown activity, often at the expense of severe toxicity that compromises palliation. This study was undertaken to test the antitumor activity and tolerability of infusional 5-fluorouracil (5-FU) modulated with low-dose oral leucovorin (LV), in heavily pretreated patients with stringent criteria of primary resistance to doxorubicin, visceral involvement, and suboptimal performance status. Twenty-six patients with measurable MBC and primary resistance to anthracyclines received a weekly outpatient 48-hour infusion of high-dose 5-FU with low dose oral leucovorin. All patients were assessable for response and toxicity. Eight partial responses were seen (30% response rate) in soft tissue and visceral sites, with a median response duration of eight months (5 + to 12). 98% of the cycles were minimally toxic or non-toxic. Toxicities included mucositis, diarrhea, and plantar-palmar-syndrome. Our results suggest that this schedule of LV-modulated infusional 5-FU can produce a substantial number of long-lasting responses and meaningful palliation to this very poor prognosis population.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationBreast Cancer Research and Treatment 50: 67–174, (1998)
dc.identifier.doihttps://doi.org/10.1023/a:1006062018355
dc.identifier.issnPrint: 0167-6806
dc.identifier.issnElectronic: 1573-7217
dc.identifier.urihttp://hdl.handle.net/10201/146104
dc.languageenges
dc.publisherSpringer
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://link.springer.com/article/10.1023/A:1006062018355
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectBiochemical modulationes
dc.subjectDoxorubicin resistant breast canceres
dc.subjectAnthracycline-resistant breast canceres
dc.subjectContinuous infusiones
dc.subject5-fluorouraciles
dc.subjectMetastatic breast canceres
dc.titleWeekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicines
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
A_1006062018355.pdf
Size:
610.96 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos